Seeking Alpha

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced commencement of the Company’s pivotal Phase 3 clinical study ...
Nasdaq

Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder

Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder (FSAD) ...
Seeking Alpha

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT will include presentations by Daré management and key opinion leaders in sexual medicine SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- Daré ...
Becker's ASC

Exalenz Bioscience, Acute Liver Failure Study Group to study use of breath test for acute liver failure: 5 points

Exalenz Bioscience is collaborating with the Acute Liver Failure Study Group. 1. Exalenz Bioscience and the Acute Liver Failure Study Group will study the ability of the BreathID Methacetin Breath ...
Hosted on MSN

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, ...
Business Insider

Bedrock Bioscience Announces Groundbreaking Medical Study Published in Prestigious Journal

CLEARWATER, Fla., Dec. 20, 2023 /PRNewswire/ -- Bedrock Bioscience is thrilled to announce the publication of a groundbreaking medical study in the esteemed International Journal of Clinical Medicine.
Business Wire

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived ...
Hosted on MSN

Skye Bioscience Reveals Phase 2a Study Results

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Skye Bioscience ( (SKYE)) has issued an ...
Business Wire

Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries

MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the company has enrolled the first patients in a Phase ...
Business Insider

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study

THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of 32.4% and maintains an average IOP reduction of 26.5% at 9 hours, significantly better ...